BR112018076175A2 - novo derivado de ácido piridonacarboxílico ou sal deste - Google Patents

novo derivado de ácido piridonacarboxílico ou sal deste

Info

Publication number
BR112018076175A2
BR112018076175A2 BR112018076175-3A BR112018076175A BR112018076175A2 BR 112018076175 A2 BR112018076175 A2 BR 112018076175A2 BR 112018076175 A BR112018076175 A BR 112018076175A BR 112018076175 A2 BR112018076175 A2 BR 112018076175A2
Authority
BR
Brazil
Prior art keywords
group
hydrogen atom
lower alkyl
salt
acid derivative
Prior art date
Application number
BR112018076175-3A
Other languages
English (en)
Inventor
Kinoshita Tomohiko
Kuramoto Yasuhiro
Inoue Satoshi
Nishimura Kouji
Hirano Tatsuya
Arai Mai
Sakurai Asuka
Kazamori Daichi
Sasaki Ayuka
Original Assignee
Wakunaga Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakunaga Pharmaceutical Co., Ltd. filed Critical Wakunaga Pharmaceutical Co., Ltd.
Publication of BR112018076175A2 publication Critical patent/BR112018076175A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

são fornecidos um novo derivado do ácido piridonacarboxílico ou um sal deste tendo um excelente efeito em bactérias tais como staphylococcus aureus, pseudomonas aeruginosa e clostridium difficile resistentes à meticilina e não sendo suscetível a bombas de efluxo de fármacos, e um agente antimicrobiano compreendendo o mesmo. um derivado do ácido piridonacarboxílico representado pela fórmula (1), em que r1 é um átomo de hidrogênio, um átomo de halogênio, um grupo alquila inferior ou um grupo amino; r2 é um grupo -nh-r6, em que r6 é um átomo de hidrogênio, um grupo alquila inferior, um grupo alquila inferior amino ou semelhantes; um grupo -o-r7, em que r7 é um átomo de hidrogênio, um grupo alquila inferior ou semelhantes; um grupo -(ch2)m-r8, em que r8 é um grupo amino ou semelhantes e m é um número inteiro de 1 a 4); ou um grupo amino cíclico representado pela seguinte fórmula (2), em que y representa nh ou c-r9ar9b, em que r9a e r9b são independentemente átomo de hidrogênio, um grupo alquila inferior, um grupo amino, um grupo amino alquila inferior ou semelhantes; e n e p são um número inteiro de 1 ou 2; r3 é um átomo de hidrogênio, um átomo de halogênio, um grupo alquila inferior ou semelhantes; r4 é um átomo de hidrogênio ou um grupo carboxila-grupo protetor; e r5 é um átomo de hidrogênio ou um grupo hidroxila-grupo protetor; ou um sal deste.
BR112018076175-3A 2016-06-15 2017-06-14 novo derivado de ácido piridonacarboxílico ou sal deste BR112018076175A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016118484 2016-06-15
JP2016-118484 2016-06-15
JP2017-056474 2017-03-22
JP2017056474 2017-03-22
PCT/JP2017/021899 WO2017217441A1 (ja) 2016-06-15 2017-06-14 新規ピリドンカルボン酸誘導体又はその塩

Publications (1)

Publication Number Publication Date
BR112018076175A2 true BR112018076175A2 (pt) 2019-03-26

Family

ID=60664281

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076175-3A BR112018076175A2 (pt) 2016-06-15 2017-06-14 novo derivado de ácido piridonacarboxílico ou sal deste

Country Status (10)

Country Link
US (1) US10532984B2 (pt)
EP (1) EP3473616A4 (pt)
JP (1) JP6322772B1 (pt)
KR (1) KR20190016962A (pt)
CN (1) CN109311818A (pt)
AU (1) AU2017285689B2 (pt)
BR (1) BR112018076175A2 (pt)
CA (1) CA3027827A1 (pt)
MX (1) MX2018015462A (pt)
WO (1) WO2017217441A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108250087B (zh) * 2018-03-15 2020-06-30 常州大学 一种4-异丁氧基苄胺的合成方法
CN109851557B (zh) * 2019-03-11 2021-01-01 江西富祥药业股份有限公司 一种西他沙星有关物质d-3的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53141286A (en) 1977-05-16 1978-12-08 Kyorin Seiyaku Kk Novel substituted quinolinecarboxylic acid
JPS5534144A (en) 1978-08-31 1980-03-10 Yuasa Battery Co Ltd Separator element
JPS5710109A (en) 1980-06-20 1982-01-19 Nippon Kogaku Kk <Nikon> Two-group constitution ftheta lens system
JPS6056959A (ja) * 1983-07-18 1985-04-02 アボツト　ラボラトリ−ズ キノリン抗菌性化合物
NZ208470A (en) 1983-07-18 1988-06-30 Abbott Lab 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such
JPS6111955A (ja) 1984-06-27 1986-01-20 Matsushita Electric Ind Co Ltd 磁気記録再生装置
US4762845A (en) * 1986-05-21 1988-08-09 Abbott Laboratories 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids
JPS6352510A (ja) 1986-08-22 1988-03-05 Toshiba Corp 電子同調チユ−ナ
JPS6362510A (ja) 1986-09-03 1988-03-18 Kurita Mach Mfg Co Ltd フイルタプレスの濾過体
US5153203A (en) 1989-03-30 1992-10-06 Wakunaga Seiyaku Kabushiki Kaisha Quinolone derivatives and salts thereof, preparation processes thereof, and antibacterial agents containing the same
JPH037260A (ja) * 1989-03-31 1991-01-14 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体またはその塩及びこれを含有する抗菌剤
WO1996012704A1 (fr) 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Nouveau derive de pyridone-carboxylate, ou sel de celui-ci, et antibacterien le contenant comme principe actif
WO1996023775A1 (fr) * 1995-01-30 1996-08-08 Wakunaga Seiyaku Kabushiki Kaisha Nouveaux derives d'acide pyridonecarboxylique ou de ses sels et agent antibacterien contenant ces derives en tant qu'ingredient actif
EP0897919B1 (en) * 1996-04-19 2004-06-16 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents containing the same as the active ingredient
MX2007005892A (es) * 2004-11-17 2007-06-19 Wakunaga Pharma Co Ltd Derivados de acido piridonacarboxilico novedosos y sales de los mismos.

Also Published As

Publication number Publication date
CN109311818A (zh) 2019-02-05
AU2017285689A1 (en) 2019-01-03
US10532984B2 (en) 2020-01-14
US20190276407A1 (en) 2019-09-12
CA3027827A1 (en) 2017-12-21
WO2017217441A1 (ja) 2017-12-21
JPWO2017217441A1 (ja) 2018-07-05
EP3473616A4 (en) 2020-02-19
AU2017285689B2 (en) 2021-01-07
MX2018015462A (es) 2019-05-27
KR20190016962A (ko) 2019-02-19
JP6322772B1 (ja) 2018-05-09
EP3473616A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
PH12018500065A1 (en) Oxysterols and methods of use thereof
BR112015026644A2 (pt) composto de tetrazolinona e uso do mesmo
PH12016502154A1 (en) Pyridazonine herbicides
PH12016501507A1 (en) Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.
MX2018015126A (es) Nuevos compuestos antibacterianos.
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112017023959A2 (pt) novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus
CO2018010787A2 (es) Compuesto de griseofulvina
PH12019500589A1 (en) Novel mesoionic insecticidal compound
BR112018074985A2 (pt) composições antibacterianas
EA201790464A1 (ru) Гетеробициклические соединения и их применение для лечения туберкулеза
BR112018076175A2 (pt) novo derivado de ácido piridonacarboxílico ou sal deste
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2019006768A (es) Peptidos antimicrobianos.
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
BR112015028871A2 (pt) novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements